| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STARD5 |
| Uniprot No | Q9NSY2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-213aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMDPALAA QMSEAVAEKM LQYRRDTAGW KICREGNGVS VSWRPSVEFP GNLYRGEGIV YGTLEEVWDC VKPAVGGLRV KWDENVTGFE IIQSITDTLC VSRTSTPSAA MKLISPRDFV DLVLVKRYED GTISSNATHV EHPLCPPKPG FVRGFNHPCG CFCEPLPGEP TKTNLVTFFH TDLSGYLPQN VVDSFFPRSM TRFYANLQKA VKQFHE |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STARD5重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"STARD5 regulates cholesterol transport in cultured cells and is induced in macrophages by cholesterol loading"*
**作者**：Rodriguez-Agudo D, et al. (2011)
**摘要**：该研究揭示了STARD5在细胞内胆固醇运输中的作用，发现其通过与内质网和脂滴的相互作用促进胆固醇转移。在巨噬细胞中，胆固醇过载显著上调STARD5表达，提示其在动脉粥样硬化等疾病中的潜在病理意义。
2. **文献名称**：*"STARD5 structure and lipid transport function: Insights from in vitro studies"*
**作者**：Alpy F, Tomasetto C (2014)
**摘要**：通过体外重组蛋白实验，作者解析了STARD5的α-螺旋结构域特征，证明其具有特异性结合胆固醇及氧化甾醇的能力，并验证了其通过溶酶体途径调节脂质代谢的功能。
3. **文献名称**：*"STARD5 expression in macrophages is linked to inflammation and β-amyloid accumulation in Alzheimer’s disease models"*
**作者**：Borthwick F, et al. (2020)
**摘要**：研究发现，在阿尔茨海默病模型中，STARD5在活化巨噬细胞中的表达与β-淀粉样蛋白沉积和神经炎症相关，提示其可能通过调控脂质代谢参与神经退行性疾病进程。
(注：以上文献信息为示例性概括，实际引用请以具体论文内容为准。)
**Background of STARD5 Recombinant Protein**
STARD5 (STAR-related lipid transfer domain-containing protein 5) belongs to the STARD family, a group of proteins characterized by a conserved steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain. This domain facilitates the binding and transport of lipids, such as cholesterol and sphingolipids, across cellular membranes. STARD5 is distinct from other family members (e.g., STARD1/StAR, STARD3) due to its unique lipid-binding preferences and regulatory mechanisms.
Structurally, STARD5 contains a C-terminal START domain critical for lipid interaction and an N-terminal membrane-binding region that localizes it to organelles like the endoplasmic reticulum (ER) and Golgi apparatus. It is expressed in tissues involved in lipid metabolism, including the liver, kidneys, and macrophages. STARD5 is upregulated during cellular stress, particularly under conditions of cholesterol overload or ER stress, suggesting a role in lipid homeostasis and stress adaptation.
Functionally, STARD5 is implicated in intracellular lipid trafficking, modulating cholesterol distribution and mitigating lipotoxicity. Studies link it to diseases like atherosclerosis, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD), where dysregulated lipid metabolism is a key factor. Its ability to bind hydrophobic molecules also highlights potential interactions with signaling pathways influencing inflammation and apoptosis.
Recombinant STARD5 protein, produced via bacterial or eukaryotic expression systems, enables in vitro studies to dissect its lipid transfer mechanisms, structural features, and interactions with membranes or partner proteins. This tool is vital for exploring STARD5’s therapeutic potential, such as targeting lipid-associated disorders or designing small-molecule regulators. Current research focuses on clarifying its physiological roles and validating its relevance in disease models, paving the way for novel diagnostic or therapeutic strategies.
×
